Search results for: Health Data and Statistics
Filter search results
How Much Should Society Pay for a New Orphan Drug? A Contribution to this Debate is now Available in a New OHE Research Paper
18 July 2018
…(England) and SMC (Scotland) regarding novel drugs approvals in our sample to collect data on patient population sizes. Although in the algebraic formulation, the authors consider a number other factors,…
Progression-free Survival as a Surrogate Outcome for Overall Survival in Oncology
4 September 2018
…method requires estimation of both trial level data (the single data-point pair per trial) and individual patient data (IPD) within trials. Yet the proportion of studies reporting the use of…
Price Transparency: Good or Bad? What Does Literature and Theory Tell Us?
17 March 2020
…London: Office of Health Economics. Available at: https://www.ohe.org/publications/who-technical-report-pricing-cancer-medicines-missing-central-role-hta-and-value Danzon, Towse and Mestre-Ferrandiz (2015). Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context” Health Econ. 24: 294–301. See OHE blog at https://www.ohe.org/news/pricing-variations-within-and-across-countries-gauging-efficiency …
Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold
12 January 2013
…systematically differ in their decision making, e.g. for historical reasons. Furthermore, no data are available on how health spending improves patients’ quality of life. There are only mortality data and…
Handling Uncertainty in the Results of Economic Evaluation
1 September 1995
…well as clinical data and offers the potential for uncertainty to be quantified through conventional statistical techniques [O’Brien,et al, 1994]. However, most economic evaluations are based largely on deterministic data…
A New Valuation Method: Directly Eliciting Personal Utility Functions
1 August 2017
…to reflect and deliberate on their preferences. A computer-based tool was developed and used to administer the questions via face-to-face interviews. The Research Paper reports the methods and findings of…
Meeting the Challenges of Drug Development in 2022: Summary of OHE’s 50th Anniversary Conference
11 October 2012
…incentives for stratified medicine and for developing efficacy and safety data for more than one indication per product Use of electronic health records, registries and other patient databases to link…
OHE at the EuroQol Plenary Meeting 2018
2 October 2018
…quality of primary care in England affects patients’ self-reported outcomes. The analysis used data from the GP Patient Survey and the national Quality and Outcomes Framework (QOF) datasets to estimate…
Comparing the EQ-5D-3L and EQ-5D-5L in a Cohort of Cancer Patients: A Research Collaboration between OHE, Curtin University and King’s College London
15 August 2017
…of the 3L and 5L instruments to different patient and disease characteristics; If the 5L instrument systematically gives different responses and values compared to 3L, and what effect this has…